Keresés eredménye

Típusa:
összetett keresés
Keresési paraméterek:
Susan M. O'Brien, MD | szakcikk |

<< < 1 > >>
2 találat 1 oldalon - ebből zárolt tartalom 2 db

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!

3054 Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Szerző: Paul M. Barr, MD1 Alessandra Tedeschi, MD2 Talha Munir, MD3 Peter Hillmen, MD, PhD4 John C Byrd, MD5 Paolo Ghia, MD, PhD6 Stephen Mulligan, MBBS, MD, FRACP, FRCPA7 Sandra Dai, PhD, MS8 Carlos Amaya-Chanaga, MD9 James P. Dean, MD, PhD10 Susan M. o'Brien, MD11
1Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY
2Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
3Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom
4The Leeds Teaching Hospitals, St. James University Hospital, (Leeds Cancer Centre, St. James' Institute of Oncology), Leeds, United Kingdom
5The Ohio State University, Columbus, OH; Comprehensive Cancer Center, The Ohio State University, Columbus, OH
6Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
7Royal North Shore Hospital, Sydney, AUS
8Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
9Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
10Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
11UC Irvine, Chao Family Comprehensive Cancer Center, Orange, CA

Background: Ibrutinib is the only once-daily Bruton’s tyrosine kinase inhibitor with significant progression-free survival (PFS) benefit demonstrated in 5 randomized phase 3 studies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) compared with standard-of-care chemotherapy and/or immunotherapy (RESONATE, RESONATE-2, iLLUMINATE, Alliance 041202, and ECOG 1912), and significant overall survival (OS) benefit in 3...

33 Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Szerző: Tait D. Shanafelt, MD1 Victoria Wang2 Neil E. Kay, MD3 Curtis A. Hanson, MD4 Susan M. O'Brien, MD5 Jacqueline C. Barrientos, MD, MS6 Diane F Jelinek, PhD7 Esteban Braggio, Ph.D.8 Jose F. Leis, MD, PhD9 Cong Christine Zhang10 Steven Coutre, MD11 Paul M. Barr, MD12 Amanda F Cashen, MD13 Anthony R. Mato, MD MSCE14 Avina Singh, MD15 Michael P. Mullane, MD16 Richard F. Little, MD, MPH17 Harry P. Erba, MD, PhD18 Richard M. Stone, MD19 Mark Litzow, MD20 Martin S. Tallman, MD21
1Stanford University, Stanford, CA
2Harvard, Boston, MA
3Division of Hematology, Mayo Clinic, Rochester, MN
4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
5Chao Family Comprehensive Cancer Center, Division of Hematology / Oncology, Department of Medicine, University of California Irvine Health, Orange, CA
6Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY
7College of Medicine, Mayo Clinic, Scottsdale, AZ
8Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
9Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
10Kaiser Permanente, Fresno, CA
11Stanford Univ. School of Med., Stanford, CA
12Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY
13Department of Medicine, Washington Univ. School of Med., Saint Louis, MO
14Center for CLL, Memorial Sloan-Kettering Cancer Center, New York, NY; CLL Program, Leukemia Service, Hematologic Malignancies Division, Memorial Sloan Kettering Cancer Center, New York, NY
15Minnesota Oncology, Burnsville, MN
16Aurora Cancer Care-Racine, Racine, WI
17National Cancer Institute, Washington; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; National Institutes of Health National Cancer Institute, Bethesda, MD
18University of Alabama at Birmingham, Birmingham, AL
19Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
20Division of Hematology, Mayo Clinic, Rochester, MN
21Memorial Sloan Kettering Cancer Center, New York, NY

BACKGROUND:Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) has been the standard therapy for younger patients with CLL. FCR therapy is particularly effective in patients with immunoglobulin heavy chain variable region (IGHV) mutated CLL. Approximately half of IGHV mutated patients are progression free 8 years after FCR therapy. At the ASH 2018 meeting, we reported the initial results of the ECOG 1912 (E1912) trial, a ...


<< < 1 > >>
2 találat 1 oldalon - ebből zárolt tartalom 2 db

A zárolt tartalmakat csak bejelentkezett felhasználók tekinthetik meg!